SCRIBE THERAPEUTICS
LIVE

Serial Number

50024120

Owner

Scribe Therapeutics Inc.

Attorney

John Paul Oleksiuk

Filing Date

Jul 31, 2026

Add to watchlist:

No watchlists yet
View on USPTO

SCRIBE THERAPEUTICS Trademark

Serial Number: 50024120

SCRIBE THERAPEUTICS is a trademark filed by Scribe Therapeutics Inc. on July 31, 2026. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Scribe Therapeutics Inc. (12 trademarks)

Alameda, CA 94501

Entity Type: 03

Trademark Details

Filing Date

July 31, 2026

Registration Date

Not Registered

Goods & Services

Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in the prevention and treatment of diseases in human therapeutics, namely, diseases caused by genetic mutations and diseases and disorders for which gene modification would ameliorate or cure; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics, namely, for the prevention and treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure related to cardiometabolic disease, cardiovascular disease, neuromuscular diseases, immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, and pain, and also for the prevention and treatment of cardiovascular, peripheral nervous system, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, cardiometabolic, neuromuscular, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, and hematologic diseases and disorders, and cancer

Filing History

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 31, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Jul 31, 2026 MAFR
NEW APPLICATION ENTERED
Jul 31, 2026 NWAP